{"groups":[{"description":"Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo radiotherapy\n\nlaboratory biomarker analysis: Correlative studies","id":"FG000","title":"Arm I (Nonmyeloablative Conditioning With Fludarabine and TBI)"},{"description":"Patients undergo TBI on day 0. All patients then undergo allogeneic peripheral blood stem cell transplantation on day 0 and receive tacrolimus PO every 12 hours on days -3 to 180, with taper on day 56, or tacrolimus IV if unable to tolerate PO; and mycophenolate mofetil PO every 12 hours on days 0-27 or mycophenolate mofetil IV if unable to tolerate PO.\n\ntotal-body irradiation: Undergo radiotherapy\n\nmycophenolate mofetil: Given IV or PO\n\ntacrolimus: Given IV or PO\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplant\n\nnonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplant\n\nlaboratory biomarker analysis: Correlative studies","id":"FG001","title":"Arm II (Nonmyeloablative Conditioning With TBI)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"100"},{"groupId":"FG001","numSubjects":"50"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"100"},{"groupId":"FG001","numSubjects":"50"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}